WilmerHale Represents Karyopharm Therapeutics in Pricing of $150M of Convertible Senior Notes

Download IconDownload Print IconPrint

WilmerHale Represents Karyopharm Therapeutics in Pricing of $150M of Convertible Senior Notes

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On Thursday, October 11, 2018, Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a clinical-stage pharmaceutical company, announced the pricing of $150 million aggregate principal amount of its 3.00% convertible senior notes due in 2025. The Notes were sold in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933. Karyopharm also granted to the initial purchasers of the Notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes.

The WilmerHale team representing Karyopharm in the sale consisted of Jason Kropp, Erika Robinson, John Sigel, Craig Hilts, Tim Kulis and Meghan Walsh. 

Read Karyopharm’s press release regarding the sale.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel